SYMPLICITY™ BLOOD PRESSURE PROCEDURE
About the Symplicity procedure
Push the barriers of high blood pressure (hypertension) with the Medtronic Symplicity blood pressure procedure, which offers a single, minimally invasive approach.
What makes the procedure different from traditional management?
- Proven safe and effective*1–3
- Keeps working 24 hours a day — like a pill you never have to remember to take2,3
Please refere to the product IFU for more details.
↓ 16.7
mmHg
In a three-year study of people who received the procedure, it helped reduce BP by 16.7 mmHg.*1
The procedure explained.
Get a brief rundown of the Symplicity blood pressure procedure.
Explore the science.
Learn more about how the Symplicity blood pressure procedure can help get your numbers down.*1–3
Adjunctive to the current management
See what happens during the Symplicity blood pressure procedure.
Set your expectations.
Important information about the benefits and risks of the Symplicity blood pressure procedure
Another way to manage your blood pressure
Find out what to expect during the day of your Symplicity blood pressure procedure.
Finally finding blood pressure control
Hear how the Symplicity blood pressure procedure made a difference in a patient’s life.
These are individual experiences. Their thoughts and opinions are their own. Not everyone will experience the same results.
Find more answers.
Dive into our FAQ about the Symplicity blood pressure procedure.
*
Includes Symplicity Spyral™
References
1
Mahfoud F, Mancia G, Schmieder R, et al. Blood pressure and MACE reductions after renal denervation: 3-year Global Symplicity Registry results. Presented at PCR e-course 2022.
2
Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. June 9, 2018;391(10137):2346–2355.
3
Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. May 2, 2020;395(10234):1444–1451.